double-blind, randomized study. All subjects who participated in the randomized study will be
offered participation in this unblinded, single-arm, safety study. Approximately 50 subjects
will be entered into the study and ENT-01 will be administered daily in escalating doses
followed by a fixed dose for 12 weeks. Each subject will participate for approximately 20
weeks; dosing duration will be approximately 14 weeks.
1. All subjects who participated in the randomized study ENT-01-030 (KARMET Stage 2
Extension subjects) and who completed the dosing period.
2. Subjects aged 30-90 years at the time of screening for the ENT-01-030 study, both
3. Subjects must provide informed consent and be willing and able to comply with study
4. Subjects must be able to read, understand, and accurately record data into the diary
to guarantee full participation in the study.
5. Female subjects must have negative serum or urine pregnancy tests and must not be
lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or
injectable) and single-barrier method, or a double-barrier method of birth control
must be used throughout the study. A vasectomized partner will be allowed as one in
conjunction with another single-barrier method.
6. Female subjects unable to bear children must have this documented in the CRF (i.e.,
tubal ligation, hysterectomy, or postmenopausal [defined as a minimum of one year
since the last menstrual period]). Post-menopausal status will be confirmed by
follicle stimulating hormone (FSH) in women less than 60 years of age.
1. Unable or unwilling to provide informed consent or to comply with study procedures.
2. Unable to withdraw proton pump inhibitors.
3. Unable or unwilling to withdraw from laxatives, opiates, clonazepam, or any
medications which may cause constipation 2 weeks prior to the dose adjustment period
and throughout the rest of the study.
4. Diagnosis of secondary constipation beyond that of Parkinson’s disease.
5. A compromised gastrointestinal system which includes:
– Structural, metabolic, or functional GI diseases or disorders.
– Acute GI illness within 2 weeks of the screening visit.
– History of major GI surgery within 30 days of the screening visit (a history of
cholecystectomy, polypectomy, hernia repair or appendicectomy are not
exclusionary as long as they were performed more than 30 days before the
6. Neurological disorder other than Parkinson’s disease that in the opinion of the
investigator might interfere with the conduct of the study.
7. On treatment with intra-jejunal dopamine or carbidopa/levodopa (i.e. Duopa).
8. Subjects starting a new Parkinson’s disease medication or modifying an existing
medication within 2 weeks prior to enrollment.
9. Unable to maintain a stable diet regimen.
10. Subjects with a cognitive impairment that preclude them from understanding the
11. Subjects placed under legal guardianship.
12. History of excessive alcohol use or substance abuse.
13. Any clinically significant abnormalities on screening laboratories or physical
examination requiring further evaluation or treatment.
14. Females who are pregnant or breastfeeding.
15. Subject or caregiver unable to administer daily oral dosing of study drug.
16. Participation in a non-Enterin investigational drug trial within the month prior to
dosing in the present study.
17. Any other reason, which in the opinion of the investigator would confound proper
interpretation of the study.
- The Parkinson’s and Movement Disorder Institute, Fountain Valley, California, United States, 92708
- SC3 Research – Pasadena, Pasadena, California, United States, 91105